Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of PD-1 Inhibition With Pembrolizumab Combined With JAK2 Inhibition in Triple Negative Breast Cancer

NCT03012230 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT03012230
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03012230 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of PD-1 Inhibition With Pembrolizumab Combined With JAK2 Inhibition in Triple Negative Breast Cancer
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Completed
Start date
December 6, 2017
Completion date
March 8, 2023
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic malignant neoplasm in the bone, stage iv breast cancer ajcc v6 and v7, triple-negative breast carcinoma